CCRN · Cross Country Healthcare, Inc.

Current Thesis

CCRN is a deal-pinned cash merger-arb, not a narrative-momentum name, and belongs in the DORMANT/pass bucket for this book. On 2026-05-06 Knox Lane a private-equity sponsor, acquiring through KL Criss Cross Intermediate, LLC agreed to take CCRN private at $13.25/share cash, ~$437M enterprise value, struck at ~17x EBITDA, a 31.06% premium to the 2026-05-06 close and ~45% to the 90-day VWAP. The stock closed $13.18 on 2026-06-05 (mkt cap $408.69M, ~31.01M sh out), leaving a ~$0.07 / ~0.5% gross spread to terms. The tape has gone bond-like; there is no 20-EMA pullback to buy and no breakout to chase. The only remaining moves are an HSR lapse that compresses the spread to zero, or a deal break that gaps the stock ~20%+ lower. Upside is mathematically capped, downside is open the wrong shape for a momentum book.

Bull Case

• Tight, high-completion-odds arb: $13.18 vs $13.25 cash = ~0.5% gross; at a guided Q3-2026 close that is only ~1.5–2% annualized, which is the market pricing very high deal confidence (announced 2026-05-06).
• Clean antitrust profile vs the failed Aya deal: Knox Lane is a financial sponsor with no competing healthcare-staffing business, so there is no horizontal-overlap theory for the FTC to chase the precise issue that sank the prior Aya Healthcare deal ($18.61/share, $615M, announced Dec-2024), which terminated 2025-12-03 when HSR clearance could not be completed (a 43-day government shutdown stalled review). Aya paid a $20M break fee.
• Board-recommended, all-cash, financed go-private: unanimous board recommendation in the PREM14A (filed ~late-May 2026); BofA Securities / Davis Polk for CCRN, MTS Health Partners / Kirkland & Ellis for Knox Lane.
• Reverse termination fee gives Knox Lane skin in the game: a $14,213,075 Parent regulatory termination fee is payable if antitrust conditions fail or Knox Lane breaches its regulatory obligations, aligning the sponsor toward closing.

Bear Case

• Asymmetric payoff that fails the >3:1 rule: best case ~$0.07/share (~0.5%); a deal break sends the stock toward standalone value of roughly $9–10 (the pre-announcement reference was ~$10.11–$10.23 on 2026-05-02), a ~22–24% drop. Risking ~22% to make ~0.5% is the inverse of this book's mandate.
• Standalone business is contracting into the buyout: Q1-2026 (reported 2026-05-07) revenue $241.1M, -17.8% YoY (vs $293.4M); net loss $4.3M / -$0.14 LPS (vs -$0.02 a year prior). Both Nurse & Allied ($201.4M) and Physician ($39.6M) segments showed lower volumes and margin compression. If the deal dies, there is no fundamental floor and the standalone re-rate likely undershoots $10.
• Second go-private attempt in 18 months: management already had one buyout collapse on regulatory timing (Aya, 2025-12-03). Residual headline sensitivity remains even with Knox Lane's cleaner profile.
• Embedded "Locums Transaction" condition: the merger closing references a related Locums (physician-staffing) Transaction; its terms are not fully spelled out in the preliminary proxy, adding a structural moving part to track before the vote.
• Zero momentum edge: RSI, MA structure, options flow and retail velocity are irrelevant on a pinned name. Capital here earns a T-bill-like return while an accelerating-narrative regime runs elsewhere idle-capital cost is the real loss.

Setup & Price Structure

• Price: $13.18 (2026-06-05 close), previous close $13.19 pinned ~7c under the $13.25 cash terms; realized vol has collapsed since the 2026-05-06 announcement.
• 52-week range: $7.43 $14.99. The $14.99 high is a relic of residual Aya-deal ($18.61) optimism that has since unwound; the $7.43 low is the standalone staffing-trough print.
• Structure: a flat arb pin, not a trend. Price only travels on deal-risk repricing a clean HSR lapse pulls it to ~$13.24–$13.25; a second request or break opens a gap toward $9–10.
• Outside date: 2026-10-06, with up to two automatic 3-month extensions to 2027-01-06 and 2027-04-06 if only HSR clearance is outstanding a long tail of deal-completion-odds risk for arb capital.

Catalyst Calendar (next 30 days)

• 2026-06-22 HSR waiting period expiry (absent a second request). The single binary in the window. A clean lapse cements completion odds and compresses the spread to ~0; a second-request announcement blows the spread out and is the primary near-term gap-down risk.
• ~late-June 2026 (est.) DEFM14A / special-meeting date. Definitive proxy expected once SEC review of the PREM14A clears; virtual special meeting at www.virtualshareholdermeeting.com/CCRN2026SM, date still TBD. Sets the shareholder-vote timeline.
• No earnings in window Q1 was reported 2026-05-07; Q2 print is ~early-August, outside 30 days. No binary print risk inside the window.

What Would Change Our Mind

• A merger-termination 8-K that depins the stock toward ~$9–10. That is the only event that turns CCRN back into a potential setup for this book and only if it pairs with a re-accelerating travel-nurse/staffing narrative (bill-rate inflation, hospital labor re-tightening). Two independent events must align; until a clean higher-low base forms post-gap it is a falling knife, not a buy.
• A topping bid (rival sponsor or strategic) above $13.25 would add upside optionality, but with Aya gone and a financed sponsor deal already inked, that is low-probability.
• An HSR second request would flip the read from "high-odds close" to "Aya rerun risk" and justify watching for the deal-break short/gap setup rather than the arb.
• Absent any of the above, a clean HSR lapse plus a $13.25 close and delisting leaves zero further upside the name simply exits the universe.

Correlation Notes

• Beta to SPY ≈ 0: once a name pins to fixed cash terms it decouples from market direction; CCRN now tracks deal-completion odds, not the tape.
• Decoupled from staffing peers: CCRN no longer trades with AMN Healthcare or the broader travel-nurse cycle the way it did pre-deal that linkage only re-establishes if the merger breaks and it re-rates on standalone fundamentals.
• Systematic risk is financing/regulatory, not equity beta: as a financed go-private, the live exposures are the leveraged-finance/credit environment (a financing-condition wobble) and FTC/HSR stance toward PE roll-ups. Widening credit spreads or an aggressive-antitrust headline are the macro tells that matter here, not equity-index moves.

Catalyst note

HSR clock (2026-06-22) is the next observable; definitive proxy/meeting date is the follow-on. Keep DORMANT/pass unless a termination 8-K depins the stock AND the staffing cycle re-accelerates.

(Themes are mislabeled in legacy tags as "health-managed-care" — CCRN is healthcare/travel-nurse STAFFING, not managed care.)

References: 2026-05-06 deal announcement & terms (BusinessWire / Modern Healthcare / InsideArbitrage); PREM14A (~late-May 2026); Q1-2026 10-Q (2026-05-07); live quote 2026-06-05.